1
|
Ren B, Dong JY, Liu Y. A New Aurone and Other Constituents From the Seeds of Psoralea corylifolia With Their Diacylglycerol Acyltransferase Inhibitory Activity. Nat Prod Commun 2019. [DOI: 10.1177/1934578x19861011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
A new aurone (1), together with 5 known compounds (2-6), were isolated from EtOAc-soluble extract of the seeds of Psoralea corylifolia. Their structures were elucidated on the basis of spectroscopic methods. All compounds were evaluated for in vitro inhibitory activity against diacylglycerol acyltransferase (DGAT). Among them, compound 1 showed selective inhibitory activity on DGAT1 with IC50 value of 54.9 ± 1.4 µM.
Collapse
Affiliation(s)
- Bo Ren
- College of Pharmacy, Chengdu University of Traditional Chinese Medicine, Sichuan Province, China
| | - Jia-Yue Dong
- College of Pharmacy, Chengdu University of Traditional Chinese Medicine, Sichuan Province, China
| | - Ying Liu
- Department of Pediatrics, West China Second Hospital of Sichuan University, China
- Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education, China
| |
Collapse
|
2
|
Qi SZ, Li N, Tuo ZD, Li JL, Xing SS, Li BB, Zhang L, Lee HS, Chen JG, Cui L. Effects of Morus root bark extract and active constituents on blood lipids in hyperlipidemia rats. JOURNAL OF ETHNOPHARMACOLOGY 2016; 180:54-9. [PMID: 26806569 DOI: 10.1016/j.jep.2016.01.024] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/09/2015] [Revised: 01/05/2016] [Accepted: 01/18/2016] [Indexed: 05/21/2023]
Abstract
OBJECTIVE Chinese crude drug Mori Cortex Radicis (the root cortex of Morus species) has been used as a folk medicine to treat hypertension, diabetes, as well as in expectorant, diuretic agents. This investigation aims to study the anti-hyperlipidemia effects of Mori Cortex Radicis (MCR) extracts in hyperlipidemic rat models and the potential therapeutic activities of compounds isolated from the extracts. MATERIALS AND METHODS The effects of MCR on hypolipidemic parameters were investigated using Wistar rats induced by high-lipid emulsion. Sixty healthy Wistar rats were randomly divided into 6 groups: normal group, hyperlipidaemia model group, simvastatin, and high-, medium- and low-dose MCR extracts. After four weeks, body weight, total cholesterol (TC), triglycerides (TG), high and low-density lipoproteins (HDL, LDL), as well as aspartate aminotransferase (AST), alanine aminotransferase (ALT) were measured. To further investigation, four major active compounds were isolated from extracts through high performance liquid chromatography (HPLC) and their diacylglycerol acyltransferase 1 (DGAT1) inhibitory activity was evaluated. RESULTS MCR dose-dependently reduced serum TC, TG, LDL-C, inhibited the activity of ALT, AST, and increased HDL-C. Furthermore, in vitro biochemistry tests revealed that four active isolates showed moderate inhibitory activity against DGAT1 with IC50 values ranging from 62.1 ± 1.2 to 99.3 ± 2.3 µM. CONCLUSIONS The results demonstrated that MCR could effectively ameliorate hyperlipidaemia and inhibit DGAT1 that a key enzyme closely related to hyperlipidaemia and type 2 diabetes. It may provide a new pharmacological basis for treating hyperlipidaemia and related diseases using MCR.
Collapse
Affiliation(s)
- Shi-Zhou Qi
- College of Pharmacy, Beihua University, Jilin City, Jilin Province 132013, Republic of China
| | - Na Li
- College of Pharmacy, Beihua University, Jilin City, Jilin Province 132013, Republic of China
| | - Zheng-Dong Tuo
- College of Pharmacy, Beihua University, Jilin City, Jilin Province 132013, Republic of China
| | - Jia-Lin Li
- College of Pharmacy, Beihua University, Jilin City, Jilin Province 132013, Republic of China
| | - Shan-Shan Xing
- College of Pharmacy, Beihua University, Jilin City, Jilin Province 132013, Republic of China
| | - Ban-Ban Li
- College of Pharmacy, Beihua University, Jilin City, Jilin Province 132013, Republic of China
| | - Le Zhang
- College of Pharmacy, Beihua University, Jilin City, Jilin Province 132013, Republic of China
| | - Hyun-Sun Lee
- Molecular Cancer Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), 685-1 Yangcheongri, Ochangeup, Cheongwongun, Chungbuk 363-883, Republic of Korea
| | - Jian-Guang Chen
- College of Pharmacy, Beihua University, Jilin City, Jilin Province 132013, Republic of China
| | - Long Cui
- College of Pharmacy, Beihua University, Jilin City, Jilin Province 132013, Republic of China.
| |
Collapse
|
3
|
Wei E, Liu B, Lin S, Liang F. Multicomponent reaction of chalcones, malononitrile and DMF leading to γ-ketoamides. Org Biomol Chem 2014; 12:6389-92. [DOI: 10.1039/c4ob00971a] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|
4
|
Naik R, Obiang-Obounou BW, Kim M, Choi Y, Lee HS, Lee K. Therapeutic Strategies for Metabolic Diseases: Small-Molecule Diacylglycerol Acyltransferase (DGAT) Inhibitors. ChemMedChem 2014; 9:2410-24. [DOI: 10.1002/cmdc.201402069] [Citation(s) in RCA: 31] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/15/2014] [Indexed: 11/07/2022]
|
5
|
Fox BM, Sugimoto K, Iio K, Yoshida A, Zhang J(K, Li K, Hao X, Labelle M, Smith ML, Rubenstein SM, Ye G, McMinn D, Jackson S, Choi R, Shan B, Ma J, Miao S, Matsui T, Ogawa N, Suzuki M, Kobayashi A, Ozeki H, Okuma C, Ishii Y, Tomimoto D, Furakawa N, Tanaka M, Matsushita M, Takahashi M, Inaba T, Sagawa S, Kayser F. Discovery of 6-Phenylpyrimido[4,5-b][1,4]oxazines as Potent and Selective Acyl CoA:Diacylglycerol Acyltransferase 1 (DGAT1) Inhibitors with in Vivo Efficacy in Rodents. J Med Chem 2014; 57:3464-83. [DOI: 10.1021/jm500135c] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Affiliation(s)
- Brian M. Fox
- Amgen Inc., 1120 Veterans Boulevard, South San Francisco, California 94080, United States
| | - Kazuyuki Sugimoto
- Central
Pharmaceutical
Research Institute, Japan Tobacco Inc., 1-1, Murasaki-cho, Takatsuki, Osaka 569-1125, Japan
| | - Kiyosei Iio
- Central
Pharmaceutical
Research Institute, Japan Tobacco Inc., 1-1, Murasaki-cho, Takatsuki, Osaka 569-1125, Japan
| | - Atsuhito Yoshida
- Central
Pharmaceutical
Research Institute, Japan Tobacco Inc., 1-1, Murasaki-cho, Takatsuki, Osaka 569-1125, Japan
| | - Jian (Ken) Zhang
- Amgen Inc., 1120 Veterans Boulevard, South San Francisco, California 94080, United States
| | - Kexue Li
- Amgen Inc., 1120 Veterans Boulevard, South San Francisco, California 94080, United States
| | - Xiaolin Hao
- Amgen Inc., 1120 Veterans Boulevard, South San Francisco, California 94080, United States
| | - Marc Labelle
- Amgen Inc., 1120 Veterans Boulevard, South San Francisco, California 94080, United States
| | - Marie-Louise Smith
- Amgen Inc., 1120 Veterans Boulevard, South San Francisco, California 94080, United States
| | - Steven M. Rubenstein
- Amgen Inc., 1120 Veterans Boulevard, South San Francisco, California 94080, United States
| | - Guosen Ye
- Amgen Inc., 1120 Veterans Boulevard, South San Francisco, California 94080, United States
| | - Dustin McMinn
- Amgen Inc., 1120 Veterans Boulevard, South San Francisco, California 94080, United States
| | - Simon Jackson
- Amgen Inc., 1120 Veterans Boulevard, South San Francisco, California 94080, United States
| | - Rebekah Choi
- Amgen Inc., 1120 Veterans Boulevard, South San Francisco, California 94080, United States
| | - Bei Shan
- Amgen Inc., 1120 Veterans Boulevard, South San Francisco, California 94080, United States
| | - Ji Ma
- Amgen Inc., 1120 Veterans Boulevard, South San Francisco, California 94080, United States
| | - Shichang Miao
- Amgen Inc., 1120 Veterans Boulevard, South San Francisco, California 94080, United States
| | - Takuya Matsui
- Central
Pharmaceutical
Research Institute, Japan Tobacco Inc., 1-1, Murasaki-cho, Takatsuki, Osaka 569-1125, Japan
| | - Nobuya Ogawa
- Central
Pharmaceutical
Research Institute, Japan Tobacco Inc., 1-1, Murasaki-cho, Takatsuki, Osaka 569-1125, Japan
| | - Masahiro Suzuki
- Central
Pharmaceutical
Research Institute, Japan Tobacco Inc., 1-1, Murasaki-cho, Takatsuki, Osaka 569-1125, Japan
| | - Akio Kobayashi
- Central
Pharmaceutical
Research Institute, Japan Tobacco Inc., 1-1, Murasaki-cho, Takatsuki, Osaka 569-1125, Japan
| | - Hidekazu Ozeki
- Central
Pharmaceutical
Research Institute, Japan Tobacco Inc., 1-1, Murasaki-cho, Takatsuki, Osaka 569-1125, Japan
| | - Chihiro Okuma
- Central
Pharmaceutical
Research Institute, Japan Tobacco Inc., 1-1, Murasaki-cho, Takatsuki, Osaka 569-1125, Japan
| | - Yukihito Ishii
- Central
Pharmaceutical
Research Institute, Japan Tobacco Inc., 1-1, Murasaki-cho, Takatsuki, Osaka 569-1125, Japan
| | - Daisuke Tomimoto
- Central
Pharmaceutical
Research Institute, Japan Tobacco Inc., 1-1, Murasaki-cho, Takatsuki, Osaka 569-1125, Japan
| | - Noboru Furakawa
- Central
Pharmaceutical
Research Institute, Japan Tobacco Inc., 1-1, Murasaki-cho, Takatsuki, Osaka 569-1125, Japan
| | - Masahiro Tanaka
- Central
Pharmaceutical
Research Institute, Japan Tobacco Inc., 1-1, Murasaki-cho, Takatsuki, Osaka 569-1125, Japan
| | - Mutsuyoshi Matsushita
- Central
Pharmaceutical
Research Institute, Japan Tobacco Inc., 1-1, Murasaki-cho, Takatsuki, Osaka 569-1125, Japan
| | - Mitsuru Takahashi
- Central
Pharmaceutical
Research Institute, Japan Tobacco Inc., 1-1, Murasaki-cho, Takatsuki, Osaka 569-1125, Japan
| | - Takashi Inaba
- Central
Pharmaceutical
Research Institute, Japan Tobacco Inc., 1-1, Murasaki-cho, Takatsuki, Osaka 569-1125, Japan
| | - Shoichi Sagawa
- Central
Pharmaceutical
Research Institute, Japan Tobacco Inc., 1-1, Murasaki-cho, Takatsuki, Osaka 569-1125, Japan
| | - Frank Kayser
- Amgen Inc., 1120 Veterans Boulevard, South San Francisco, California 94080, United States
| |
Collapse
|
6
|
Acyltransferases and transacylases that determine the fatty acid composition of glycerolipids and the metabolism of bioactive lipid mediators in mammalian cells and model organisms. Prog Lipid Res 2014; 53:18-81. [DOI: 10.1016/j.plipres.2013.10.001] [Citation(s) in RCA: 160] [Impact Index Per Article: 16.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/02/2012] [Revised: 07/20/2013] [Accepted: 10/01/2013] [Indexed: 12/21/2022]
|
7
|
Lee K, Kim M, Lee B, Goo J, Kim J, Naik R, Seo JH, Kim MO, Byun Y, Song GY, Lee HS, Choi Y. Discovery of indolyl acrylamide derivatives as human diacylglycerol acyltransferase-2 selective inhibitors. Org Biomol Chem 2012; 11:849-58. [PMID: 23242135 DOI: 10.1039/c2ob27114a] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
A series of indolyl acrylamide derivatives was synthesized as potential diacylglycerol acyltransferase (DGAT) inhibitors. Furfurylamine containing indolyl acrylamide derivative 5h exhibited the most potent DGAT inhibitory activity using microsomes prepared from rat liver. Further evaluation against human DGAT-1 and DGAT-2 identified indolyl acrylamide analogues as selective inhibitors against human DGAT-2. In addition, the most potent compound 5h inhibited triglyceride synthesis dose-dependently in HepG2 cell lines.
Collapse
Affiliation(s)
- Kyeong Lee
- College of Pharmacy, Dongguk University-Seoul, Seoul 100-715, Korea
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Barlind JG, Bauer UA, Birch AM, Birtles S, Buckett LK, Butlin RJ, Davies RDM, Eriksson JW, Hammond CD, Hovland R, Johannesson P, Johansson MJ, Kemmitt PD, Lindmark BT, Morentin Gutierrez P, Noeske TA, Nordin A, O’Donnell CJ, Petersson AU, Redzic A, Turnbull AV, Vinblad J. Design and Optimization of Pyrazinecarboxamide-Based Inhibitors of Diacylglycerol Acyltransferase 1 (DGAT1) Leading to a Clinical Candidate Dimethylpyrazinecarboxamide Phenylcyclohexylacetic Acid (AZD7687). J Med Chem 2012; 55:10610-29. [DOI: 10.1021/jm301296t] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Jonas G. Barlind
- Cardiovascular and Gastrointestinal Innovative Medicines Unit Mölndal, AstraZeneca R&D, S-431 83 Mölndal, Sweden
| | - Udo A. Bauer
- Cardiovascular and Gastrointestinal Innovative Medicines Unit Mölndal, AstraZeneca R&D, S-431 83 Mölndal, Sweden
| | - Alan M. Birch
- AstraZeneca R&D, Alderley Park, Macclesfield, Cheshire, SK10 4TG, U.K
| | - Susan Birtles
- AstraZeneca R&D, Alderley Park, Macclesfield, Cheshire, SK10 4TG, U.K
| | - Linda K. Buckett
- AstraZeneca R&D, Alderley Park, Macclesfield, Cheshire, SK10 4TG, U.K
| | - Roger J. Butlin
- AstraZeneca R&D, Alderley Park, Macclesfield, Cheshire, SK10 4TG, U.K
| | | | - Jan W. Eriksson
- Cardiovascular and Gastrointestinal Innovative Medicines Unit Mölndal, AstraZeneca R&D, S-431 83 Mölndal, Sweden
- Department of Molecular and Clinical
Medicine, Sahlgrenska University Hospital, S-413 45 Gothenburg, Sweden
| | - Clare D. Hammond
- AstraZeneca R&D, Alderley Park, Macclesfield, Cheshire, SK10 4TG, U.K
| | - Ragnar Hovland
- Cardiovascular and Gastrointestinal Innovative Medicines Unit Mölndal, AstraZeneca R&D, S-431 83 Mölndal, Sweden
| | - Petra Johannesson
- Cardiovascular and Gastrointestinal Innovative Medicines Unit Mölndal, AstraZeneca R&D, S-431 83 Mölndal, Sweden
| | - Magnus J. Johansson
- Cardiovascular and Gastrointestinal Innovative Medicines Unit Mölndal, AstraZeneca R&D, S-431 83 Mölndal, Sweden
| | - Paul D. Kemmitt
- AstraZeneca R&D, Alderley Park, Macclesfield, Cheshire, SK10 4TG, U.K
| | - Bo T. Lindmark
- Cardiovascular and Gastrointestinal Innovative Medicines Unit Mölndal, AstraZeneca R&D, S-431 83 Mölndal, Sweden
| | | | - Tobias A. Noeske
- Cardiovascular and Gastrointestinal Innovative Medicines Unit Mölndal, AstraZeneca R&D, S-431 83 Mölndal, Sweden
| | - Andreas Nordin
- Cardiovascular and Gastrointestinal Innovative Medicines Unit Mölndal, AstraZeneca R&D, S-431 83 Mölndal, Sweden
| | | | - Annika U. Petersson
- Cardiovascular and Gastrointestinal Innovative Medicines Unit Mölndal, AstraZeneca R&D, S-431 83 Mölndal, Sweden
| | - Alma Redzic
- Cardiovascular and Gastrointestinal Innovative Medicines Unit Mölndal, AstraZeneca R&D, S-431 83 Mölndal, Sweden
| | | | - Johanna Vinblad
- Cardiovascular and Gastrointestinal Innovative Medicines Unit Mölndal, AstraZeneca R&D, S-431 83 Mölndal, Sweden
| |
Collapse
|
9
|
The chylomicron: relationship to atherosclerosis. Int J Vasc Med 2011; 2012:784536. [PMID: 22007304 PMCID: PMC3189596 DOI: 10.1155/2012/784536] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2011] [Accepted: 08/08/2011] [Indexed: 12/20/2022] Open
Abstract
The B-containing lipoproteins are the transporters of cholesterol, and the evidence suggests that the apo B48-containing postprandial chylomicron particles and the triglyceride-rich very low density lipoprotein (VLDL) particles play an important part in the development of the plaque both directly and indirectly by their impact on LDL composition. The ratio of dietary to synthesised cholesterol is variable but tightly regulated: hence intervention with diet at best reduces serum cholesterol by <20% andusually <10%. Statins are the mainstay of cholesterol reduction therapy, but they increase cholesterol absorption, an example of the relationship between synthesis and absorption. Inhibition of cholesterol absorption with Ezetimibe, an inhibitor of Niemann Pick C1-like 1 (NPC1-L1), the major regulator of cholesterol absorption, increases cholesterol synthesis and hence the value of adding an inhibitor of cholesterol absorption to an inhibitor of cholesterol synthesis. Apo B48, the structural protein of the chylomicron particle, is synthesised in abundance so that the release of these particles is dependent on the amount of cholesterol and triglyceride available in the intestine. This paper will discuss cholesterol absorption and synthesis, chylomicron formation, and the effect of postprandial lipoproteins on factors involved in atherosclerosis.
Collapse
|
10
|
Yamamoto T, Yamaguchi H, Miki H, Shimada M, Nakada Y, Ogino M, Asano K, Aoki K, Tamura N, Masago M, Kato K. Coenzyme A: diacylglycerol acyltransferase 1 inhibitor ameliorates obesity, liver steatosis, and lipid metabolism abnormality in KKAy mice fed high-fat or high-carbohydrate diets. Eur J Pharmacol 2010; 640:243-9. [PMID: 20478303 DOI: 10.1016/j.ejphar.2010.04.050] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2009] [Revised: 03/17/2010] [Accepted: 04/23/2010] [Indexed: 10/19/2022]
Abstract
Coenzyme A (CoA):diacylglycerol acyltransferase 1 (DGAT1) is 1 of the 2 known DGAT enzymes that catalyze the final and only committed step in triacylglycerol synthesis; this enzyme is considered to be a potential therapeutic target in metabolic disorders such as obesity and its related lipid abnormalities. Compound-Z, a novel specific small-molecule DGAT1 inhibitor, significantly reduced adipose tissue weight and tended to hepatic lipid accumulation in genetically obese KKAy mice. These actions were shown to almost the same extent in both a high-fat feeding condition in which triacylglycerols are synthesized mainly via exogenous fatty acid and a low-fat, high-carbohydrate feeding condition in which triacylglycerols are synthesized mainly via de novo fatty acid synthesis. This inhibitor also significantly reduced plasma and/or hepatic cholesterol levels in KKAy mice in a high-fat feeding condition. This cholesterol-lowering effect was suggested to be due to mainly decreases in cholesterol absorption from the small intestine. These results suggest that Compound-Z is a promising and attractive agent not only for the treatment of obesity but also hepatic steatosis and circulating lipid abnormalities that are the leading causes of atherosclerosis.
Collapse
Affiliation(s)
- Toshihiro Yamamoto
- Pharmacology Research Laboratories, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, Osaka, Japan.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Nakada Y, Aicher TD, Le Huerou Y, Turner T, Pratt SA, Gonzales SS, Boyd SA, Miki H, Yamamoto T, Yamaguchi H, Kato K, Kitamura S. Novel acyl coenzyme A (CoA): diacylglycerol acyltransferase-1 inhibitors: synthesis and biological activities of diacylethylenediamine derivatives. Bioorg Med Chem 2010; 18:2785-95. [PMID: 20207151 DOI: 10.1016/j.bmc.2010.01.067] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/25/2009] [Revised: 01/28/2010] [Accepted: 01/29/2010] [Indexed: 11/28/2022]
Abstract
A series of diacylethylenediamine derivatives were synthesized and evaluated for their inhibitory activity against DGAT-1 and pharmacokinetic profile to discover new small molecule DGAT-1 inhibitors. Among the compounds, N-[2-({[1-phenyl-3-(trifluoromethyl)-1H-pyrazol-4-yl]carbonyl}amino)ethyl]-6-(2,2,2-trifluoroethoxy)pyridine-3-carboxamide 3x showed potent inhibitory activity and excellent PK profile. Oral administration of 3x to mice with dietary-induced obesity resulted in reduced body weight gain and white adipose tissue weight.
Collapse
Affiliation(s)
- Yoshihisa Nakada
- Medicinal Chemistry Research Laboratories, Takeda Pharmaceutical Company Ltd, 2-17-85, Jusohonmachi, Yodogawa-ku, Osaka 532-8686, Japan.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|